Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008

摘要: Study Type – Harm (Cohort) Level of Evidence 2b What’s known on the subject? and What does study add? In clinical trials, oral medications for BPH have been effective at managing LUTS preventing progression to urinary retention, infections, renal insufficiency. Population-level trends these adverse outcomes are poorly characterized. We identified a 400% increase in hospitalizations with acute failure, indicating that severe events persist despite widespread use therapies USA. OBJECTIVE • To determine if (AEs) benign prostatic hyperplasia (BPH) declined tandem increased therapy. MATERIALS AND METHODS • We used Nationwide Inpatient Sample, 20% sample USA community hospitals, weighted estimate national numbers characterize prevalence AEs from 1998 2008. • We calculated age-adjusted associated conditions analyzed regression modelling. RESULTS • Of 134 million estimated eligible discharges during period, 7 464 730 (5.6%) had either primary or secondary diagnosis BPH. • The among all hospitalizations, irrespective diagnosis, 4.3% 8% (P < 0.001) period. • The as decreased 0.88% 0.48% 0.001). • Discharges surgery 51% (odds ratio [OR] 0.49, 95% confidence interval [CI] 0.45–0.54, P-trend (OR 4.28, CI 3.22–5.71, <0.001). • There were no significant changes retention (P-trend = 0.636), bladder stones 0.117), infection 0.101) over time. CONCLUSIONS • Increased failure stable other indicate USA. • Further studies needed explain trends.